Novobiocin is believed to act in several ways in a bactericidal manner. It inhibits bacterial DNA gyrase, interfering with protein and nucleic acid synthesis and also interferes with bacterial cell wall synthesis. Activity of the drug is enhanced in an alkaline medium. The spectrum of activity of novobiocin includes some grampositive cocci (Staphs _,_ Streptococcus pneumonia, and some group A streps). Activity is variable against other streptococci and weak against the Enterococci. Most gram-negative organisms are resistant to the drug, but some _Haemophilus_ spp., _Neisseria_ spp., and _Proteus_ spp. may be susceptible.
Orally administered nystatin is used primarily for the treatment of oral or gastrointestinal tract Candida infections in dogs, cats, and birds; it has been used less commonly in other species for the same indications.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
核對活性本體與鈉鹽、標示強度基準、所有複方成分、確切成品與標籤版本 核對動物種類、乾乳或泌乳階段、病原或適應症、司法管轄、現行核准與販售狀態 核對途徑、劑型、處方、監測與停用條件，以及食用動物殘留與停藥要求
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。